Veritas Aortic Solutions has raised $12m to advance its technology for the treatment of aortic root and ascending aorta pathologies.
Veritas’ seed financing round was led by a group of angel investors, with additional participation from Cedars-Sinai Intellectual Property Company, along with existing investors of inQB8 Medical Technologies, which Veritas spun out from in late 2025.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The proceeds will support the continued development of Veritas’ transcatheter valved aortic root conduit (TVARC) technology through first-in-human clinical use, the company stated.
TVARC is under development to provide interventional, non-surgical treatment for high-risk root and ascending aortic diseases, including dissections, aneurysms, and other pathologies that specifically involve the aortic root, coronary ostia, and/or the ascending aorta.
Conceived as a single, permanent implant combining a bioprosthetic aortic valve, ascending aortic graft, and Veritas’s Chameleon Eye coronary perfusion ports, TVARC’s overall purpose is to seal off diseased or damaged parts of the aorta and restore healthy blood flow to the coronary arteries and the rest of the body.
Including a transfemoral delivery catheter, TVARC is being developed with the aim of eliminating the need for open-heart surgery and allowing for precise positioning and controlled deployment of Veritas’ implant.
Acute pathologies of the aortic root and ascending aorta – such as aneurysms and acute dissections – are associated with high mortality rates of up to 65% due to complications including arterial tears and ruptures during surgical treatment.
Veritas’s CMO, Arshad Quadri, commented: “As a cardiac surgeon myself, I have performed these procedures numerous times. They are complex, challenging, and highly invasive. Endovascular options for the descending aorta and the arch have been available for a long time, but open-heart surgery remains the only approved option for patients with root and ascending aortic pathologies.
“It has always been a dream of mine to be able to offer these patients a faster, safer, less-invasive option, and today we are one step closer to making that a reality.”
